ELN --- J D Edwards' estimate of 7% of US market and 6% of European market is pathetically skinny when you realize that the PML scare in Feb 2005 has by subsequent investigation revealed CONCLUSIVELY that there were NO PML CASES RESULTING FROM TYSABRI MONOTHERAPY IN ALL CLINICAL DATA. If the drug is remarketed, the monotherapy usage alone will far surpass the J D Edwards estimates of market share. JMO